This Advances article focuses on progress in the field of primary immunodeficiency diseases (PIDDs) published in 2017. In addition to reporting new gene defects associated with PIDDs characterized by an increased susceptibility to infections, other recently described PIDDs have been found to present with significant autoimmune and inflammatory manifestations, which are often of more concern than the increased risk of infection.
FOLLICULAR HELPER H CELLS

Follicular helper T (T FH ) cells have a prominent role in B-cell
terminal differentiation to memory B cells and plasma cells, which takes place in germinal centers, and the subsequent development of antigen-specific antibody responses (Fig 1) . IL-12 and IL-21 stimulation induces differentiation of T FH cells, which are identified by expression of CXCR5, CXCL13, inducible T-cell costimulator (ICOS), programmed cell death 1, B-cell lymphoma 6, B-and T-lymphocyte attenuator, and SLAM-associated protein. Increased numbers of peripheral T FH -like cells have been described in patients with autoimmune disorders, including psoriasis, lupus erythematosus, and rheumatoid arthritis. Conversely, impaired differentiation of T FH cells has been reported in patients with PIDDs, such as ICOS deficiency and immunodeficiencies caused by signal transducer and activator of transcription 1 (STAT1) gain-offunction (GOF) and STAT3 loss-of-function mutations. Current research efforts are aimed at further characterizing the induction and regulation of these cells.
Hosokawa et al 1 reported IL-21 protein expression by IkBNS (encoded by NFKB inhibitor delta, NFKBID) binding to the IL21 gene promoter site in CD4 T cells. Previous data suggested that overexpression of achaete-scute homologue 2 (ASCL2) induces T-cell differentiation into T FH cells. 2 Interestingly, it has been shown that IkBNS-null T cells overexpressing ASCL2 do not develop into T FH cells, whereas overexpression of both IkBNS and ASCL2 rescues the phenotype. These data indicate that IkBNS might act downstream of the ASCL2 transcription signal pathway.
T FH cell differentiation induced by coculture with thymic stromal lymphopoietin-activated dendritic cells was reported by Pattarini et al. 3 They further characterized OX40 ligand as the most essential cell-to-cell ligand for this process and found that the resulting antibody class secretion was predominantly IgE, suggesting that this interaction results in T H 2 bias. Achour et al 4 reported the negative influence of regulatory B cells on T FH cell differentiation induced by IL-12 and IL-21 in vitro, with both decreasing expression of surface markers and their capacity to induce B-cell differentiation and antibody production. The presence of regulatory B cells was associated with an expansion of follicular regulatory T (Treg) cells, which were characterized by simultaneous expression of programmed cell death 1, CXCR5, and forkhead box protein 3.
Because of the importance of ICOS-ICOS ligand (ICOSL) binding to mediate B-cell differentiation and antibody production by T FH cells, Lownik et al 5 asked whether proteases involved in shedding of ICOSL from B cells could affect antibody production. They found that a disintegrin and metalloprotease 10 (ADAM10), but not ADAM17, was the most significant enzyme that participated in cleavage of ICOSL and therefore in activation of B-cell differentiation in germinal centers. By using mouse models, both ADAM10 and ADAM17 were shown to cleave ICOSL; however, most of the effect could be attributed to ADAM10 alone.
Given the role of T FH cells in autoimmune conditions and antibody deficiencies (Table I) , 6 elucidation of these molecular mechanisms, including the cytokines involved, could lead to the development of strategies helpful in the diagnosis and management of disorders of antibody production.
NUCLEAR FACTOR kB SUBUNIT 1 IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY
Deleterious monoallelic mutations in the gene encoding nuclear factor kB (NF-kB) subunit 1 (NF-kB1; p105/p50) have been demonstrated in patients with common variable immunodeficiency (CVID) and were reported to be the most common genetic defect in a large cohort of 390 patients with CVID, accounting for 16 (4%) cases. 7 Patients with these mutations present with reduced NF-kB1 protein levels and an expanded CD21 low B-cell subset compared with healthy control subjects. Clinical presentation was variable, with autosomal dominant inheritance and variable penetrance. A penetrance of 60% was found in a cohort of 18 subjects carrying familial NFKB1 mutations.
In a study conducted in 3 families in Finland, 8 12 of 15 subjects carrying NFKB1 mutations (H67R, R157X, and I553M) had disease, resulting in a penetrance of 80%, clinical variability, and a strong environmental and/or polygenic influence in the clinical presentation of CVID. In addition to defective antibody responses, affected patients in these families presented with inflammatory bowel disease, Behçet disease, and vasculitis (Fig 2 and Table II) . 7, 8 Keller et al 9 reported that B cells from some patients with CVID have impaired NF-kB1 signaling and calcium mobilization after B-cell receptor stimulation. This impairment was most significant in those patients with an expanded CD21 low CD38 low B-cell subset and was associated with reduced IkBa degradation. These patients had increased frequency of autoimmunity. Of note, CD21 low CD38 low B-cell expansion has been described in patients with HIV infection and autoimmune conditions, such as lupus erythematous. CD21 low CD38 low B cells from patients with lupus also show reduced IkBa degradation, suggesting that this is characteristic of the cell type.
Lougaris et al 10 reported 2 patients with CVID with monoallelic NFKB1 mutations (A506Vfs and D191L), leading to a truncated p50 protein and absent p105, expansion of CD21 low CD38 low B cells, and autoimmune enteropathy. Taken together, these data contribute to the characterization of the subset of patients with CVID who have inflammatory and autoimmune complications, who are likely to present with an expansion of CD21 low CD38 low B cells and can have monoallelic mutations in NFKB1.
IMMUNE CONSEQUENCES OF SPLENECTOMY AND NEONATAL THYMECTOMY
The immune consequences of splenectomy and neonatal thymectomy are summarized in Table III. 11 -15 Patients who have been splenectomized are considered to be at significant risk of severe bacterial infections, even after pneumococcal immunization. Karasatova et al 11 investigated the anti-pneumococcal-specific lymphoproliferation in patients who have been splenectomized after spleen trauma to determine whether T-cell function was impaired. After pneumococcal immunization, there was a decrease in antigen-specific lymphoproliferation, which was most significant for the T H 1 cell subset, suggesting that the spleen is important for optimizing both T-and B-cell responses. Asplenic children with heterotaxy syndrome similarly have a significantly increased risk of invasive bacterial infections compared with patients with heterotaxy syndrome with a normal spleen or polysplenia (50% vs 8%, respectively). However, when parameters of B-cell immunity were investigated, there were no significant differences between these 2 groups with respect to switched memory B cells, immunoglobulin levels, and antigen-specific antibody responses. 12 The clinical consequences of neonatal thymectomy continue to be investigated. It is uncertain whether the mild-to-moderate T-cell lymphopenia that follows complete thymectomy in some infants undergoing heart surgery is a risk factor for autoimmunity and increased susceptibility to infection. 13 Silva et al 14 studied 7 young adults who were thymectomized in infancy and did not find clinical manifestations of autoimmunity or increased allergic disease; however, they presented with positive autoantibody profiles, which might confer future risk of disease.
Gudmundsdottir et al 15 studied the clonality of T-and B-cell repertoires in 11 patients 18 years after thymectomy. Compared with healthy control subjects, CD4 and CD8 T cells had higher measures of clonality in thymectomized patients, and the degree of clonality was inversely correlated with the number of naive T cells. B-cell repertoire was not affected. Possible explanations include the relative preservation of Treg cells and limited follow-up. Both the degree of clonality and the presence of autoantibodies might be predictors of future autoimmune conditions and be best characterized by prolonged follow-up.
AUTOIMMUNITY AND INFLAMMATION IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES
Recent findings on autoimmunity and inflammation in patients with primary immunodeficiencies (PIDDs), are shown in Table IV . [16] [17] [18] [19] [20] [21] [22] [23] [24] Familial Mediterranean fever (FMF) is caused by a genetic defect in the familial Mediterranean fever gene (MEFV), resulting in a deficiency of pyrin, a protein that plays a role in inflammation and infections. FMF is characterized by episodes of inflammation triggered by emotional or physical stress. Using transcriptomic analysis in neutrophils sampled from patients with FMF during attacks and in remission, Skendros et al 16 focused on overexpression of the protein regulated in development and DNA damage responses 1 (REDD1). During autophagy, an intracellular vesicle develops to enclose cytoplasmic components and fuses with lysosomes to form the autolysosome, where contents are degraded. Autolysosomes that are induced by REDD1 activation contain pyrin and the NLRP3 inflammasome. Inflammasomes are multiprotein complexes that assemble in macrophages after different stimuli, such as bacterial products. These complexes activate the expression and secretion of inflammatory mediators. A mutated pyrin impairs autolysosome formation, resulting in increased IL-1b secretion and neutrophil extracellular trap release. REDD1 is expressed in response to epinephrine stimulation, usually during stress conditions, which might explain the association of stress and episodes of inflammation in patients with FMF. A proteomics study in the THP-1 macrophage cell line and in primary monocyte-derived macrophages stimulated with LPS showed that Bruton tyrosine kinase (BTK), a signal transducer essential for B-cell development, also regulates activation of the NLRP3 inflammasome. 17 Testing cells from patients with X-linked agammaglobulinemia or cells from healthy control subjects exposed to ibrutinib, a BTK inhibitor, resulted in reduced IL-1 secretion and inhibition of the inflammasome.
Ito et al 25 reported that BTK inhibitors reduced IL-1 secretion in LPS-primed mouse peritoneal macrophages and also in macrophages stimulated by other NLRP3 inflammasome activators but not when stimulated by poly(deoxyadenylic-deoxythymidylic), an activator of the AIM2 inflammasome. Therefore BTK is necessary for activation of the NLRPR3 inflammasome, and BTK inhibitors currently used in the treatment of B-cell lymphomas are now proposed for use in the management of NLRP3-mediated autoimmune and inflammatory conditions.
The role of DNA demethylation in activation of the inflammasome was explored by Vento-Torno et al. 18 LPS stimulation was shown to be associated with demethylation of the inflammasome genes IL1B, IL1A, NLRC5, AIM2, and CASP1. By inhibiting Tet oncogene family, member 2 (TET2), a regulator of gene demethylation, secretion of IL-1b was downregulated, providing a novel pathway to inhibit mechanisms of inflammation.
Widdrington et al 26 reported reduced TNF-a secretion by LPS-primed THP-1 macrophages caused by mitochondrial DNA damage, a process often observed in sepsis. Other findings included decreased Toll-like receptor 4 cell-surface expression and decreased interferon secretion. These changes were partially reversed when IFN-g was added to the cell cultures. The authors suggest that these mechanisms might be of significance in patients with sepsis, and there might be a role for the use of IFN-g to reverse the immunosuppression often observed during these events.
Autoimmune and inflammatory manifestations are being recognized in patients with PIDDs as much as their characteristic susceptibility to infections. Fischer et al 19 at the Le Centre Reference Deficits Immunitaires Hereditaires French national PIDD registry study group reported that the frequency of autoimmune disorders in 2183 patients with PIDDs was as high as 26%. Autoimmune cytopenia was at least 120 times more frequent than in the general population. Other frequent autoimmune/inflammatory diseases include inflammatory bowel disease and arthritis. The greatest risk for these manifestations was in patients with T-cell deficiencies and CVID. Survival was reduced in those patients presenting with autoimmunity and inflammation.
Analysis of specific PIDDs reveals distinct profiles with regard to inflammation. In the chronic granulomatous disease (CGD) French cohort, 71 of 81 patients with CGD had an inflammatory condition, 20 and in an Israeli CGD cohort, 50% of these events involved the gastrointestinal tract. 27 Autoimmunity has also been reported in X-linked CGD carriers. Battersby et al 21 identified 81 X-linked CGD female carriers in the United Kingdom CGD registry. Sixty-three (79%) subjects reported autoimmune skin conditions: photosensitivity, rashes, and eczema. Three of the carriers had inflammatory bowel disease, and 18% were given a diagnosis of a lupus-like disorder.
Marciano et al 22 reported on a cohort of 93 X-linked CGD carriers followed at the National Institutes of Health. Thirty-one (33%) patients reported autoimmune or inflammatory symptoms, including discoid lupus erythematosus, photosensitivity, and gastrointestinal symptoms. The difference in frequency of autoimmunity reported in both cohorts might be explained by the reporting definition of autoimmunity. Although autoimmunity was not associated with oxidative burst capacity, as measured by using the dihydrorhodamine assay, an increased frequency of infections was observed in X-linked CGD carriers with less than 20% dihydrorhodamine-positive cells.
In a study of 8 patients with leukocyte adhesion deficiency (LAD), 28 6 had autoantibodies and 3 had autoimmune conditions: autoimmune diabetes, autoimmune hemolytic anemia, and Crohn-like colitis and arthritis. The experience with this small cohort suggests that patients with LAD are at risk for autoimmunity; a larger experience is needed to define this risk.
Moutsopoulous et al 23 reported successful use of ustekinumab, an mAb that inhibits IL-12 and IL-23, in a 19-year-old patient with LAD and chronic severe gingival ulcers and a sacral ulcer. The researchers had previously found increased secretion of IL-17 and IL-23 in periodontal lesions from patients with LAD and in animal models. Clinical improvement was observed after 3 weeks of treatment. After a year, all lesions healed, suggesting a significant role of neutrophils in the regulation of inflammation. Monoallelic mutations in the IKAROS family zinc finger protein 1 (IKZF1) gene have been shown to cause B-cell deficiency and variable hypogammaglobulinemia. 24, 29 Hoshino et al 30 found that 4 of 9 patients with IKZF1 mutations had autoimmune disease: immune thrombocytopenic purpura, IgA vasculitis, and systemic lupus erythematosus. The development of autoimmune and inflammatory manifestations in patients with PIDDs is mostly attributed to impaired mechanisms of immune tolerance, including Treg cells.
Evidence of defective Treg cell activity was studied in patients with immunodeficiency caused by recombination-activating gene mutations. 31 Recombination-activating gene-deficient Treg cells demonstrated a reduced repertoire and reduced capacity to suppress T-cell activation compared with control Treg cells, suggesting a novel mechanism participating in the development of autoimmunity.
RECENTLY REPORTED PIDDs
The Primary Immunodeficiency Diseases Committee of the International Union of Immunological Societies convened in February 2017 and issued update reports on the traditional and phenotypic classification of PIDDs. 32, 33 There have been 354 recorded inborn errors of immunity and 344 recorded genes linked to PIDDs. The term ''inborn error of immunity'' was introduced to include conditions that are not mainly characterized by susceptibility to infections, such as autoinflammatory conditions. The identification of genes causing PIDDs is fueled by ''nonbiased'' molecular approaches using whole-exome sequencing (WES) and copy number variant analysis by using a microarray. In a cohort of 278 families with PIDDs of unknown genetic cause, this approach identified a candidate molecular cause in 110 (40%) cases, leading to management changes in 60 cases. 34 Eight of these cases were identified by using copy number variant analysis. This study demonstrates the value of using these molecular approaches that is at least similar to the diagnoses obtained by using targeted sequencing in this scenario, with the advantage of possibly identifying causative genes not previously described. When the severe combined immunodeficiency (SCID) phenotype is clear, targeted gene sequencing for known genes can be considered before WES, considering that a minority (10% to 15%) of SCID cases remain without a genetic diagnosis.
Newly described gene defects causing PIDDs (Table V) 35-51
include exostosin-like 3 (EXTL3), TNF-a-induced protein 3 (TNFAIP3 [A20]), actin-related protein 2/3 complex-subunit 1B (ARPC1B), hypoxia upregulated 1 (HYOU1), BTB domain and CNC homolog 2 (BACH2), CD70, and CD55. WES performed in patients with skeletal dysplasia, developmental delay, and variable T-cell immunodeficiency demonstrated missense mutations in EXTL3, a glycosyltransferase involved in heparan sulfate biosynthesis. [35] [36] [37] Fibroblasts from affected patients showed increased fibroblast growth factor 2 signaling and reduced IL-2-induced STAT5 phosphorylation. These defects were reversed with expression of normal EXTL3 protein. Enzymatic activity of EXTL3 was shown to be severely reduced. Thymus development in zebrafish with EXTL3 mutations was reduced compared with that in control zebrafish embryos.
TNFAIP3 (A20) downregulates activation of the NF-kB pathway by acting upstream of NF-kB essential modulator, a regulatory subunit of the IkB kinase complex. Zhou et al 38 reported that heterozygous loss-of-function mutations in TNFAIP3 (HA20) can cause an autoinflammatory disease. These mutations induce increased NF-kB signaling and phosphorylation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinases. TNFAIP3 (HA20)-associated mutations were found in 6 unrelated families who mostly presented with childhood-onset systemic inflammation and a Behçet-like disorder.
By using WES in an infant with lymphadenopathy, splenomegaly, and persistent fever, Takagi et al 39 found a biallelic mutation in the TNFAIP3 (HA20) gene, predicting a truncated protein. Phosphorylation of IkB kinase and NF-kB was increased in patient-derived T cells. Mutant TNFAIP3 (HA20)-transfected cells showed increased TNF receptor-associated factor 6 polyubiquitination, suggesting loss of TNFAIP3 (A20) deubiquitination activity. Cohort studies have further defined the spectrum of clinical manifestations of TNFAIP3 (A20) deficiency, including Behçet disease, Crohn disease, periodic fever with aphthous pharyngitis and adenitis, polyarticular juvenile idiopathic arthritis, and psoriatic arthritis. [40] [41] Badran et al 42 identified a heterozygous splicing mutation in v-Rel avian reticuloendotheliosis viral oncogene homolog A (RELA), encoding the NF-kB subunit RelA that segregated with autosomal dominant mucocutaneous ulcerations dependent on anti-TNF inhibitors. Patients had reduced RelA expression and increased TNF-induced cell death in fibroblasts but not in lymphocytes. This report supports the essential role of RelA to maintain the epithelial barriers and regulate TNF-induced cell death in chronic patients with mucocutaneous ulcerations. The Arp2/3 complex is essential in actin polymerization, endocytosis, and cytokinesis. Two of the 7 subunits are actin-related proteins of the Arp2 and Arp3 subfamilies. The other 5 regulatory subunits are actin-related protein complex (ARPC) 1, ARPC2, ARPC3, ARPC4, and ARPC5. Three groups independently reported that ARPC1B mutations led to an inflammatory syndrome with platelet developmental arrest. [43] [44] [45] Patients had small-volume platelets, similar to those in patients with Wiskott-Aldrich syndrome. They also had vasculitis and inflammatory bowel disease. Because the isoform ARPC1B is expressed exclusively in hematopoietic cells, defects are not seen in fibroblasts or other cell lines that express ARPC1A. A zebrafish model reproduced the findings, and wild-type ARPC1B was able to rescue platelet and T-cell development.
In a patient with a history of recurrent oral herpesvirus infections and recurrent hypoglycemia, Haapaniemi et al 46 found compound heterozygous missense mutations in the HYOU1 gene using WES analysis. The patient had neutropenia that resolved with granulocyte colony-stimulating formula treatment and was receiving immunoglobulin replacement because of the use of rituximab to treat Takayasu arteritis. Mutant HYOU1 proteins showed ectopic protein binding and altered expression of proteins involved in oxidative metabolism.
Afzali et al 47 used WES analysis in 3 patients with a history of early-onset autoimmune gastrointestinal disease and found heterozygous mutations in BACH2. All 3 had a CVID picture with absent antibody responses to vaccinations. BACH2 regulates the control T-cell effector lineages and promotes Treg cells. BACH2-deficient mice showed absent Treg cells and an excess of memory/effector T cells, resulting in autoimmunity. Class-switch recombination was also impaired. The authors concluded that BACH2 haploinsufficiency accounts for the defect of antibody response and autoimmunity.
Two groups independently reported the association of CD70 deficiency and high susceptibility to EBV-induced lymphomas. 48, 49 They demonstrated reduced antiviral T-cell cytotoxicity similar to that previously observed in patients with CD27 deficiency, underscoring the role of CD27-CD70 interaction for antiviral immunity.
Homozygous deleterious mutations in CD55 were associated with complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy syndrome in 11 patients, who were first investigated because of early-onset inflammatory bowel disease. 50 Five of the patients presented with hypogammaglobulinemia and frequent respiratory tract infections. CD55 is also known as complement decayaccelerating factor that helps to control damage to host cells. This study showed that absence of CD55 leads to complement hyperactivation in T cells, which could be reversed with CD55 reconstitution. Kurolap et al 51 reported 6 patients from a large family presenting early in life with protein-losing enteropathy, thrombopathy, and absent CD55 expression. Treatment of 3 of these patients with eculizumab (anti-CD5 mAb) resulted in a marked reduction in complement activation, an increase in serum albumin and protein concentrations, and a reduction in the number of stools.
CARTILAGE-HAIR HYPOPLASIA
Cartilage-hair hypoplasia (CHH) is a skeletal disorder characterized by short-limb dwarfism, sparse hair, variable immune deficiency, and a high risk of infection and neoplasia. Kostjukovits et al 52 reported a cohort of 56 Finnish adult and pediatric patients with CHH carrying the g.70A>G mutation in the RNA component of the mitochondrial RNA processing endonuclease (RMRP) gene. Analysis of clinical data showed that 15 (27%) did not have symptoms of immunodeficiency, 26 (47%) had respiratory tract infections, and 15 (27%) had combined immunodeficiency. Only 7 patients received antibiotic prophylaxis and immunoglobulin supplementation. These findings confirm previous reports of lack of correlation between clinical presentation and antibody function. The report also cautions regarding possible increased severity of clinical disease with age. Bronchiectasis was found in 10 (29%) of 34 adult patients with CHH associated with a history of tobacco smoking but not with antibody defects, allergic disease, or respiratory tract infections. 53 Deficiency of telomere homeostasis results in bone marrow failure and immunodeficiency. Because of the molecular binding of RMRP and telomerase reverse transcriptase, 2 studies examined whether telomere length was shortened. 54, 55 Compared with matched healthy control subjects, median telomere length in peripheral blood cells was significantly shorter in patients with CHH but not in mutation carriers. Both telomere length and telomerase activity were affected in lymphocytes from patients with CHH. The mechanisms for these findings are still not clearly defined and might have implications with worsening of clinical symptoms with age.
ACTIVATED PHOSPHOINOSITIDE 3-KINASE d SYNDROME Activated phosphoinositide 3-kinase d syndrome (APDS) is an autosomal dominant immune disorder caused by GOF mutations in phosphatidylinositol 3-kinase, catalytic, delta (PIK3CD), which encodes the p110d catalytic subunit of phosphoinositide 3-kinase d (PI3Kd). Affected patients present with a persistent and dysregulated cell activation state, with impairment of both T-and B-cell differentiation and function. In a cohort of 53 patients with APDS, 56 sinopulmonary infections (98%) and nonneoplastic lymphoproliferation (75%) were the most commonly observed conditions. Other common complications included herpesvirus infections (49%), autoinflammatory disease (34%), and lymphoma (13%). Neurodevelopmental delay was reported in 19% of the cohort, suggesting a possible role for PI3Kd in the central nervous system. Immunologic testing did not identify markers associated with clinical severity. Most patients received immunoglobulin replacement and antibiotic prophylaxis. Fifty patients carried the previously reported PIK3CD E1021K allele, and 3 patients had the E525K allele.
Dulau Florea et al 57 described impaired B-cell differentiation in the bone marrow of 10 patients with APDS, with B-cell lymphopenia in peripheral blood and predominance of transitional B cells, which is consistent with the frequent presentation of APDS as CVID.
Different immunosuppressive therapies have been used for lymphoproliferative manifestations in patients with APDS. Rapamycin is an attractive candidate because of the mechanisms involving mammalian target of rapamycin (mTOR) pathways. A cohort study of 77 European patients with APDS caused by mutations in PIK3CD (APDS1; n 5 51) or PIK3R1 (APDS2: n 5 22) described the clinical response to rapamycin: lymphoproliferation was significantly reduced (8 completely, 11 partially, and 6 with no remission), but bowel inflammation and cytopenias were not as successfully treated in most patients (3 completely, 3 partially, and 9 with no remission). Specific inhibition of PI3Kd has shown clinical benefit in certain types of B-cell lymphomas, and several small molecules with this property have been developed. 58 A 12-week dose-escalating open-label clinical trial of leniolisib, a novel PI3K inhibitor, was conducted in 6 patients with APDS. 59 Overall, patients showed a decrease in IgM and inflammatory marker levels and normalization of transitional and naive B cells. One patient stopped immunoglobulin supplementation. All patients showed reduction of lymph node size and spleen volume by 40%. There was recovery of cytopenias, whereas neutropenia, transaminitis, and diarrhea, toxicities commonly associated with PI3K inhibitors, did not occur.
The experience of 11 patients with APDS who received hematopoietic stem cell transplantation (HSCT) because of severe immunodeficiency and presenting with recurrent infections and lymphadenopathy was reported. 60 Nine (81%) patients are alive with a post-HSCT follow-up of 8 months to 16 years. Two deaths occurred about 3 months after HSCT because of cytomegalovirus (CMV) and adenovirus pneumonias, and 1 patient died of idiopathic pulmonary fibrosis.
HSCT FOR PIDDs
Advances on HSCT for PIDDs, are listed in Table VI . [61] [62] [63] [64] The experience of HSCT for PIDDs continues to improve over time, as reflected in several reports summarized here. Heimall et al 61 representing the Primary Immune Deficiency Treatment Consortium published a multicenter prospective observational study of HSCT for SCID performed from 2010 to 2014 in the United States and Canada; 68 patients with SCID and 32 patients with leaky SCID were included. Two-year survival was greater than 90%, with no significant differences when considering donor source selection, conditioning, or graft-versus-host disease prophylaxis. Two-year survival was 80% for those undergoing transplantation after 3.5 months of age with an active infection.
This result in infected patients older than 3.5 months represents a significant improvement over a previous Primary Immune Deficiency Treatment Consortium retrospective study of patients with SCID undergoing transplantation from 2000 through 2009, 71 in which the survival was 67%. In the prospective study, 25 (42%) of 59 patients given a diagnosis early with newborn screening or family history had an active infection before HSCT, highlighting the need to improve preventive measures. At 100 days after T cell-replete HSCT, the risk of death or the need for a second HSCT by 2 years after HSCT was associated with T-cell counts of less than 300 cells/mL, CD8 T-cell counts of less than 50 cells/mL, CD45RA T cells of less than 10%, and polyclonal Vb families of less than 13 of 24 (33% vs 11%, P 5 .048). Consistent with these results, a review of 273 patients receiving HSCT for a variety of malignant and nonmalignant diseases (12% with PIDDs) indicated that a delay in CD4 T-cell reconstitution was associated with reactivation of adenovirus, EBV, and human herpesvirus 6 but not CMV or BK virus. 72 Dvorak et al 62 reviewed the frequency of neurologic symptoms (developmental delay, seizures, hemiplegia, cerebral palsy, and blindness) in 62 patients with SCID from a single center who received HSCT and survived. They measured the neurological event-free survival and found that it was 100% at 5 years in those patients given a diagnosis based on family history or newborn screening (n 5 31). In contrast, 8 (26%) of 31 patients with SCID given a clinical diagnosis (ie, presenting with infections) had neurological impairment associated with pre-HSCT infections with CMV, respiratory syncytial virus, Candida species, or bacterial pneumonia (neurological event-free survival 5 51% at 5 years, P < .001). This study indicates that outcomes in addition to overall survival are important in assessing various treatment approaches and further supports the benefit of newborn screening by preventing neurological damage in patients with SCID.
De la Morena et al 63 reported on a large international cohort of 176 patients with X-linked hyper-IgM syndrome from 28 centers who were given a diagnosis between 1964 and 2013. Thirty-eight percent were treated with HSCT. No difference in overall survival was observed with regard to HSCT versus medical management across all years; however, there was a tendency to favor HSCT treatment when considering only those treated after 1993. Also, patients treated with HSCT at an early age had improved survival. Liver disease and age at transplantation of greater than 10 years were negative risk factors for survival.
Miot et al 64 gathered the worldwide experience of patients with hypomorphic NF-kB essential modulator (NEMO) mutations who received HSCT and presented a cohort of 29 patients from which 10 patients were not previously reported. The engraftment rate was 93%, with 74% survival. The small number of patients did not allow for strong conclusions; however, the data suggested that using a carrier sister or mother as donor, mycobacterial infection before transplantation, and the presence of inflammatory bowel disease were risk factors for poor posttransplantation outcomes.
Successful HSCT has been reported for rare primary immunodeficiencies. In 2 siblings with Myb-like, SWIRM, and MPN domains 1 (MYSM1) deficiency, Bahrami et al 65 used a regimen based on fludarabine and treosulfan in consideration of the increased susceptibility to genotoxic stress. Ovadia et al 66 reported HSCT in 2 siblings with RelB deficiency presenting with severe T-cell deficiency and recurrent infections. They received HSCT from a matched unrelated donor with myeloablative conditioning, resulting in immunoreconstitution.
GENE THERAPY FOR PIDDs
For more information on gene therapy for PIDDs, see Table VI . [67] [68] [69] [70] Shaw et al 67 reported the long-term outcomes of 10 patients with adenosine deaminase (ADA) deficiency who enrolled in a gene therapy trial between 2009 and 2012. All patients received ADA-corrected autologous hematopoietic stem cells after receiving conditioning with low-dose busulfan and stopping enzyme replacement therapy. Nine of 10 patients remained off enzyme replacement therapy and had normal lymphocyte counts and proliferative responses to mitogens at the time of the report. Three of these 9 patients also stopped immunoglobin supplementation. In a safety evaluation study genomic DNA from 15 patients with ADA treated with gene therapy using gammaretroviral-based vectors was examined for integration-site distribution. The 2 sites most frequently found were in the MDS and EVI1 complex locus (MECOM) and in LIM domain only 2 (LMO2), near gene promoters, at sites previously observed in gene therapy trials for IL-2 receptor g (IL2RG) SCID, Wiskott-Aldrich syndrome, and CGD. 68 Vector-site integration diversity correlated with T-cell clonal diversity and T-cell repertoire, as measured by using vector integration site sequencing and T-cell receptor b-chain rearrangement sequencing. The degree of vector integration diversity correlated significantly with exposure to busulfan preconditioning, as measured by using the cumulative area under the curve, and with CD34 1 cell dose. The authors concluded that vector insertions in oncogenes alone do not result in neoplasias because none have been seen in the gene therapy trials for ADA-SCID to date, and it is possible that the nature of the ADA gene defect might have a role in the lack of development of leukemias even when gammaretroviral vectors were used.
Significant preclinical progress towards the use of gene therapy for CGD was reported. Sweeney et al 69 had a phagocyte defective mouse model in nonobese diabetic gc 2/2 SCID (NOD-SCID) mice for evaluating human gene therapy for X-linked CGD using the technology with clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) to knock out exon 1 of the murine cytochrome b, beta subunit (Cybb) gene. They subsequently demonstrated the significance of retaining intron 1 sequences to allow expression of CYBB in granulocytes from induced pluripotent stem cells from patients with CGD with mutations in exon 5 when using an endogenous promoter. 73 The targeted insertion of the normal sequence of a CYBB minigene (exons 2-13) into these induced pluripotent stem cell-derived granulocytes restored gp91phox activity. When the CYBB minigene was inserted into CYBB exon 1, there was no detectable expression, although expression was obtained when it was inserted into exon 2.
De Ravin et al 74 reported CRISPR/Cas9-mediated repair of the CYBB C676T position in mobilized CD34
1 hematopoietic stem cells (HSCs) from 2 patients carrying this mutation and allowed differentiation into myeloid cells in vitro. Correction efficiency was 19%, as measured based on oxidative capacity, compared with 95% of myeloid cells derived from an HSC control. There were no off-target insertions or deletions detected by using exome sequencing. Transplantation of gene-repaired human X-linked CGD CD34
1 HSCs into NOD-SCID mice resulted in development of functional mature human myeloid and lymphoid cells for up to 20 weeks, with a functional oxidative capacity of about 14% of human myeloid cells. HSCs from a second patient with CGD showed a similar degree of correction. This work helps to establish the feasibility of the CRISPR-based approach for genetic correction of CGD and possibly other blood cell diseases.
Preclinical investigations in advancing gene therapy for SCID included development of a lentiviral vector with the human Artemis DCLRE1C cDNA under transcriptional regulation of its own human Artemis promoter. 70 Overexpression of Artemis with highly active promoters resulted in toxicity to transduced cells, and therefore use of the autologous gene promoter was expected to be better tolerated. Transduction of human Artemis-deficient fibroblasts and CD34
1 HSCs, as well as HSCs from Artemis-deficient mice, achieved significant correction of radiation sensitivity and successful in vivo and in vitro differentiation of transduced Artemis-deficient HSCs into T and B cells.
Parallel to the efforts for gene-editing approaches for CGD, strategies based on homology-directed repair are being optimized for SCID. Schiroli et al 75 established a humanized mouse model to test gene editing in human hematopoietic stem cells. They used an adeno-associated virus 6 or a defective lentivirus to carry donor DNA and an electroporated zinc finger nuclease to insert a mini-IL2RG gene into the IL2RG locus aimed at correcting the greatest number of mutations in this gene with one strategy.
OTHER THERAPIES FOR PIDDs
Results of a series of 12 European patients with complete DiGeorge syndrome who received thymus transplants from 2009 and 2014 were reported by Davies et al. 76 T-cell reconstitution occurred 5 to 6 months after transplantation. Two patients died of pre-existing viral infections, and 1 died from autoimmune thrombocytopenia. Autoimmune complications were seen in 7 of 12 patients, including hemolytic anemia, neutropenia, thrombocytopenia, and thyroiditis. These outcomes support the effectiveness of thymus transplantation for patients with complete DiGeorge syndrome, although concerns for the development of autoimmunity are raised.
Marciano et al 77 studied the use of granulocyte transfusions over the past 3 decades in a cohort of 48 patients with CGD presenting with refractory infections. The treatment was associated with resolution in 51 of 58 infectious episodes. Analysis of multiple variables, including granulocyte dose, type of infection, genetic diagnosis, and demographics, suggested that lack of response was associated with older age and providing this treatment late in the course of the infection.
A deeper understanding of mechanisms of disease prompt use of biological agents for novel applications in patients with PIDDs. Weinacht et al 78 reported the use of ruxolitinib, a Janus kinase 1/2 inhibitor, to control autoimmune cytopenias in a patient with a STAT1 GOF mutation. Immunologic correlates were demonstrated, including modulation of type I and II interferons, restoration of T H 1 and T FH cell responses, and improvement in T H 17 differentiation. Tabellini et al 79 reported that natural killer (NK) cell dysfunction in these patients was related to unresponsiveness to IL-15.
Vargas-Hernandez et al 80 demonstrated that use of ruxolitinib restored normal expression of perforin in NK cells and improved NK cell function in patients with STAT1 GOF mutations.
Innovative therapeutic interventions are needed for patients with PIDDs. Measures of quality of life indicate that current management is accompanied by suboptimal well-being. In a study of 945 patients with CVID recruited by the Immune Deficiency Foundation, 81 there was significantly decreased mental and physical well-being compared with that in the general US adult population normative sample independent of the mode of immunoglobulin replacement. Similar decreased quality-of-life measures were found in children with PIDDs. 82 
CONCLUSIONS
New developments in the biology of T FH cells help us understand their role in the regulation of B-cell responses and suggest points of intervention. In parallel, studies of NFKB1 mutations showed that intrinsic pathways of B-cell activation are in part responsible for expansion of immature cells and can result in CVID. WES technology has contributed to the discovery of new genes that are essential to the immune response, with gene mutations being responsible not only for the high susceptibility to infections but also for the increased risk of autoimmunity and autoinflammation. Improved outcomes of HSCT for SCID reflect awareness, as well as implementation of universal newborn screening for T-cell deficiency. Gene therapy researchers have brought new ideas to reduce genotoxicity by using CRISPR/ Cas9 and other gene-editing technologies and gene insertion by using autologous promoters.
